Bill Jackson, Ph.D. of BioTex, Inc., the parent company of Ice Nine Biotechnologies has received a Phase 2 SBIR grant of $1M from the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) to further the development of a platform for “Massively Parallel Selection of Aptamers”.  The underlying technology has the potential to revolutionize the rapid availability of custom aptamer affinity reagents for research, clinical diagnostics, and even therapeutics.